Why Werewolf Therapeutics, Inc.’s (HOWL) Stock Is Up 9.05%
As of Friday, December 19, Werewolf Therapeutics, Inc.’s HOWL share price has surged by 9.05%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why Werewolf Therapeutics, Inc.’s (HOWL) Stock Is Down 41.36%
As of Thursday, December 18, Werewolf Therapeutics, Inc.’s HOWL share price has dipped by 41.36%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Werewolf Therapeutics, Inc.’s (HOWL) Stock Is Down 43.07%
As of Thursday, December 18, Werewolf Therapeutics, Inc.’s HOWL share price has dipped by 43.07%, which has investors questioning if this is right time to buy.Tudor Pop
Why Werewolf Therapeutics, Inc.’s (HOWL) Stock Is Up 8.80%
As of Wednesday, December 17, Werewolf Therapeutics, Inc.’s HOWL share price has surged by 8.80%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Werewolf Therapeutics, Inc.’s (HOWL) Stock Is Down 7.35%
As of Thursday, November 13, Werewolf Therapeutics, Inc.’s HOWL share price has dipped by 7.35%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | HOWL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $17.2 | $252.6 | 9% |
|
| Shares Out (Mil) | 48.6 | 52.3 | 47% |
|
| Institutional Ownership | 93.9% | 92.1% | 64% |
|
| Float (Mil) | 47.9 | 40.2 | 46% |
|
| Beta | 0.27 | 0.95 | 16% |
|
| Avg Daily Volume (000s) | 950 | 455 | 70% |
|
| Price Change (52-week) |
(70.6%) | 52.9% | 9% |
|
| Growth | HOWL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (32.3%) | (9.9%) | 12% |
|
| EPS (5yr) | 45.7% | 16.0% | 91 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (15.6%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | na | |
| Current EPS | ($0.320) | ($1.270) | na | |
| Month Ago EPS | ($0.320) | ($1.270) | na | |
| # Rev Up | 1 | 1 | na | |
| # Rev Down | 0 | 0 | na | |
| Three Months Ago EPS | ($0.300) | ($1.080) | na | |
| Year/Year Chg | 14.3% | (4.3%) | na | |
| Financials | HOWL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($56) | ($43) | 15% |
|
| EPS (TTM) | ($1.198) | ($1.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($52) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $7 | $5 | 27% |
|
| Enterprise Value (Q1) (Mil) | $9 | $180 | 7% |
|
| Valuation | HOWL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.41 | 2.56 | 37% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | HOWL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (68.1%) | (49.8%) | 8% |
|
| ROE | (161.9%) | (55.5%) | 5% |
|
| Liabilities to Assets | 79.0% | 30.3% | 74% |
|
| F-Score | 2 | 3 | 7% |
|
Werewolf Therapeutics, Inc. did not pass any screens on 7/31/2026.
